Your session is about to expire
← Back to Search
MT-1186 for Lou Gehrig's Disease
Study Summary
This trial is testing a drug to treat ALS, and is assessing its long-term safety and tolerability.
- Lou Gehrig's Disease
Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2021 Phase 3 trial • 185 Patients • NCT04165824Trial Design
Find a Location
Who is running the clinical trial?
Frequently Asked Questions
Are there any other treatments like this that have been tried before?
"MT-1186 has undergone 9 clinical trials in 94 cities across 10 countries. The first trial was sponsored by Mitsubishi Tanabe Pharma Development America, Inc. in 2020 and completed Phase 3 drug approval that year. A total of 140 participants were involved. Since then, 26 more trials have been completed."
What is the American federal government's opinion of MT-1186?
"Since this is a Phase 3 trial, there is available data that suggests MT-1186 is safe as well as evidence from multiple rounds of testing that support this claim."
Do we have any prior data to refer to regarding MT-1186?
"MT-1186 was first investigated in 2020 at the Walter Mackenzie Health Sciences Centre (WCM) in Alberta. So far, there have been 26 completed clinical trials. 9 more are ongoing, with many taking place in Milwaukee, Wisconsin."
Share this study with friends
Copy Link
Messenger